How many insider trades does FilingIQ track for ALLO?

FilingIQ tracks 326 Form 4 insider transactions for ALLO (Allogene Therapeutics, Inc.), covering filings from Oct 15, 2018 onwards. 5 of those were filed in the last 90 days.

Are ALLO insiders net buyers or net sellers?

Across the full Form 4 history for ALLO, 13 transactions (4%) were open-market purchases and 133 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ALLO insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ALLO in?

Allogene Therapeutics, Inc. (ALLO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $457.33M.

ALLO insider trading

Healthcare

Allogene Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

326

Last 90 days

Buys / sells

4% / 41%

Market cap

$457.33M

About Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Company website: allogene.com

ALLO insider activity at a glance

FilingIQ has scored 326 insider transactions for ALLO since Oct 15, 2018. The most recent filing in our index is dated Apr 21, 2026.

Across the full history, 13 open-market purchases and 133 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ALLO insider trades is 55.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ALLO trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading ALLO

Chang David D

4 trades · score 69.0

Frequently asked

How many insider trades does FilingIQ track for ALLO?: FilingIQ tracks 326 Form 4 insider transactions for ALLO (Allogene Therapeutics, Inc.), covering filings from Oct 15, 2018 onwards. 5 of those were filed in the last 90 days.
Are ALLO insiders net buyers or net sellers?: Across the full Form 4 history for ALLO, 13 transactions (4%) were open-market purchases and 133 (41%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ALLO insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ALLO in?: Allogene Therapeutics, Inc. (ALLO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $457.33M.

Methodology & sources

Every ALLO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.